Stockwatch: Almost all roads lead to M&A
This article was originally published in Scrip
Executive Summary
Second-quarter earnings season turned on a sixpence last week. After the worries of falling sales, earnings and currencies from the previous two weeks, suddenly the world was a better place with all roads leading to mergers and acquisitions (M&A). Indeed, if you believed all the research published by investment bank analysts last week, all the life science sector's ills can be cured by M&A – although rationally that can't be true since we would eventually end up with only one life science company.